Literature DB >> 27119148

On Retinal Gene Therapy.

M Dominik Fischer1.   

Abstract

Mutations in a large number of genes cause retinal degeneration and blindness with no cure currently available. Retinal gene therapy has evolved over the last decades to become a promising new treatment paradigm for these rare disorders. This article reflects on the ideas and concepts arising from basic science towards the translation of retinal gene therapy into the clinical realm. It describes the advances and present thinking on the efficacy of current clinical trials and discusses potential roadblocks and solutions for the future of retinal gene therapy.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27119148     DOI: 10.1159/000445782

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  3 in total

Review 1.  Statement of the DOG, the RG, and the BVA on the therapeutic use of voretigene neparvovec (Luxturna™) in ophthalmology. English version : January 2019.

Authors: 
Journal:  Ophthalmologe       Date:  2020-01       Impact factor: 1.059

2.  RPE-derived exosomes rescue the photoreceptors during retina degeneration: an intraocular approach to deliver exosomes into the subretinal space.

Authors:  Yange Wang; Qian Zhang; Guoqing Yang; Yuanmeng Wei; Miao Li; Enming Du; Haijun Li; Zongming Song; Ye Tao
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

3.  Longitudinal Evaluation of Hyper-Reflective Foci in the Retina Following Subretinal Delivery of Adeno-Associated Virus in Non-Human Primates.

Authors:  Eduardo Rodríguez-Bocanegra; Fabian Wozar; Immanuel P Seitz; Felix F L Reichel; Alex Ochakovski; Kirsten Bucher; Barbara Wilhelm; K Ulrich Bartz-Schmidt; Tobias Peters; M Dominik Fischer
Journal:  Transl Vis Sci Technol       Date:  2021-05-03       Impact factor: 3.283

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.